PEY21 UTILITY ASSESSMENT AMONG PATIENTS WITH DRY EYE DISEASE IN THE UK  by Buchholz, P et al.
A180 Abstracts
CONCLUSIONS: It proved practical and feasible to use DCEs
as a basis of quality weights within a programme speciﬁc QALY
framework. Important areas for future research include devel-
oping proﬁle measures into index measures, ensuring realistic
designs that satisfy both statistical and respondent efﬁciency 
and anchoring at full health and death for use within a QALY
framework.
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OBJECTIVES: Age-related macular degeneration (AMD) is the
leading cause of blindness in the developed countries and
accounted for 8.7 million cases of blindness around the world in
2002. Insufﬁcient documentation of the impact of AMD on
patients and their caregivers limits our understanding of the
disease burden. The objective of this study is to document the
humanistic and economic impact of exudative (wet) AMD on
elderly subjects and compare it to a population group not
affected by the disease. METHODS: This is a multinational,
cross-sectional, observational study of self-reported functional
health and disease burden among elderly subjects with and
without subfoveal, exudative AMD. Each of the ﬁve participat-
ing countries, Canada, France, Germany, Spain, and the UK, will
recruit 100 bilateral AMD patients and 100 controls. The
primary objective is to compare the difference in humanistic
impact as measured by the National Eye Institute Visual Func-
tion Questionnaire (NEI-VFQ25) between AMD patients and
control group of similar age patients in general medical care.
Other end points include assessment of the disparity in health-
related quality of life burden due to wet AMD compared to non-
AMD controls using the EuroQol and Hospital Anxiety and
Depression Scale. Information on resource utilization and eco-
nomic impact of AMD on patients and caregivers will be col-
lected form physicians and patients. RESULTS: Data collection
began in April 2005 and is expected to complete by November
2005. Final analysis will use standard bivariate and multivariate
methods to explore relationships between severity of AMD and
sociodemographic characteristics, health-related quality of life,
depression, falls, and resource utilization variables. Summary
analysis will be conducted in aggregate and by country. CON-
CLUSIONS: Analysis of a wide range of factors affecting AMD
patients will provide useful guidance to health care providers,
payers, and AMD support groups when determining the beneﬁts
of emerging therapies for wet AMD.
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OBJECTIVE: To assess the impact of best and worst eye visual
acuity (VA) on vision-speciﬁc health-related quality of life
(HRQol) and utility in patients with wet Age-Related Macular
Degeneration (AMD) METHODS: A cross-sectional study was
carried out in three European countries: France, Germany, Italy.
Patients were enrolled when they visited a participating retina
specialist. VA at diagnosis and at inclusion was collected. Two
HRQoL instruments were administered at the visit day: the
National Eye Institute Visual Function Questionnaire—25 items
(NEI-VFQ-25), and the Health Utility index (HUI). Patients were
stratiﬁed into four groups of severity using two VA thresholds,
20/40 for the best eye (BE) and 20/200 for the worst eye (WE).
Analysis of variance was performed on QoL and utility scores to
estimate the impact of each eye adjusted on age, gender and
country. RESULTS: 360 patients were included, mainly females
(60%). Mean age and time since AMD diagnosis was respec-
tively 77 years and 2.3 years. At inclusion, mean VA was 0.49
LogMar for BE and 1.0 LogMar for WE. HUIs mean scores
decreased with severity from 0.62 to 0.39 for HUI3 and from
0.76 to 0.63 for HUI2. For both utility indexes, scores were
mainly linked to BE VA. The NEI-VFQ-25 scale also exhibits a
decreasing trend in the global score as VA decreases. Mean global
score varied from 67.0 for the less severe group to 47.0 for the
more severe one. Global NEI-VFQ-25 score was signiﬁcantly
affected by BE and WE VA (BE p < 0.0001; WE p = 0.0306).
This contribution was also observed for the General vision, 
distance vision, driving, and mental health subscales. CON-
CLUSION: HRQoL and utility scores decreased with the dete-
rioration of VA. BE VA and WE VA is two independent factors
of vision-related QoL. Vision preservation in both eyes should
maintain QoL for AMD patients.
PEY21
UTILITY ASSESSMENT AMONG PATIENTS WITH DRY EYE
DISEASE IN THE UK
Buchholz P1, Steeds C2, Stern LS3,Wiederkehr DP3, Doyle JJ3,
Katz LM3, Figueiredo FC4
1Allergan, Ettlingen, Germany; 2Consultant, Motherwell, UK; 3Analytica
International, New York, NY, USA; 4Royal Victoria Inﬁrmary, Newcastle
Upon Tyne, England
OBJECTIVES: To determine and compare utility values (patient
preferences) associated with dry eye disease with other disease
utilities. METHODS: Forty-four patients with mild to severe dry
eye attending a tertiary specialist dry eye clinic in the UK were
surveyed via interactive utility assessment software. Utility values
were measured by the time trade-off (TTO), standard gamble
(SG), and rating scale (RS) methods and adjusted to scores from
1.0 = perfect health to 0.0 = death. Patients reported utilities for:
self-reported current dry eye status, self-reported current comor-
bidities, various dry eye severities, and binocular and monocu-
lar painful blindness. Visual functioning and ocular symptoms
were assessed by the 25-Item National Eye Institute Visual 
Function Questionnaire and the Ocular Surface Disease Index.
Patient dry eye severity was independently classiﬁed by patient
and physician assessments. Pearson correlation coefﬁcients were
computed for patients’ self-reported dry eye utility and physi-
cian-reported severity. Agreement between self-reported and
physician-reported patient severity was analyzed (Kappa).
RESULTS: Patients reported higher utilities for their current dry
eye condition than for monocular and binocular blindness
(SG:0.84 > 0.60 > 0.51; TTO:0.67 > 0.43 > 0.38; RS:0.55 > 0.37
> 0.24). Using TTO, the mean score for asymptomatic dry eye
(0.68) was similar to that for “some physical and role limitations
with occasional pain” and severe dry eye requiring surgery
scored (0.56) similarly to hospital dialysis (0.56–0.59). Utilities
described by patients of other dry eye severity levels were similar
for patients self-reported as mild to moderate versus those self-
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reported as severe. For current dry eye condition, mean utilities
for these groups were 0.72 for self-reported mild to moderate
and 0.61 for self-reported severe. CONCLUSIONS: Utilities for
dry eye were in the range of conditions accepted as lowering
health utilities. Severe dry eye utilities were similar to those
reported for dialysis and severe angina. Findings highlight the
impact of dry eye on patients.
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OBJECTIVE: Ophthalmologists have to face various acute or
chronic painful diseases. They miss speciﬁc tools assessing ocular
pain. Our objective was to develop and validate a tool to quickly
and precisely describe patient’s complaint, measure pain inten-
sity and elicit possible causes. METHODS: Different types of
quantiﬁcation and description of pain identiﬁed from the litera-
ture were proposed to 20 patients suffering from acute or chronic
painful ophthalmic diseases. A questionnaire was developed, val-
idated by an Advisory Committee (AC) and tested with 8 other
patients. The pilot questionnaire was produced and validated by
the AC. A cross-sectional, observational study was carried out
to validate the questionnaire for a use in clinical practice and to
provide a typology of painful ocular pathologies. The question-
naire was completed by 536 consecutive patients presenting with
pain complaint in 43 centres. The clinicians completed a medical
form and assessed the questionnaire’s usefulness and feasibility
in clinical practice. RESULTS: The test questionnaire was devel-
oped taking into account the preference given by patients to
visual analogous or graduated scales to quantify pain, and to pic-
tograms to describe pain. This test version was considered valid
and easy to use, except for the emotional descriptors of pain.
The pilot questionnaire contained ﬁve sections: “General
Health”, “Eyes and eyesight”, “Pain”, “Pain relief”, “Pic-
tograms and sensorial descriptors”. A description of pain char-
acteristics was provided for the most frequent painful diseases,
including traumatisms (183), ocular surface diseases (71), cornea
pathologies (58). A total of 27 ophthalmologists evaluated the
questionnaire and 78% of them considered it helpful for patient
management. CONCLUSION: The ODEON® questionnaire is
a unique, promising tool designed for use in clinical practice to
allow patients with ocular pain to comprehensively quantify and
describe their pain in a standardised format. Further work is
needed to establish speciﬁc recommendations.
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OBJECTIVES: To compare the results of a prospective cost-
beneﬁt analysis (CBA) of the South Carolina Palmetto Poison
Center (PPC) using Bayesian and frequentist (inferential) statis-
tical approaches to estimation. METHODS: Results from a cost-
beneﬁt analysis of a statewide poison control center were used
in this analysis. The CBA was conducted based on a follow-up
survey of 652 callers to the PPC who were recommended for
home management of their suspected poisoning exposure. A
payor perspective was taken and costs included direct costs. Ben-
eﬁts were measured as direct medical costs avoided (e.g. emer-
gency department visit, ambulance service, physician visit) by the
use of the PPC. A series of decision analytic models were con-
structed and analyzed separately with frequentist and Bayesian
statistical methods. Data from a similar CBA of the PPC con-
ducted in 1998 was used to obtain the “prior” information
needed for the Bayesian analysis. BC ratios using the two
approaches were compared and their interpretations explored.
RESULTS: Calculation of BC ratios using Bayesian and fre-
quentist approaches yielded similar measures. The BC ratio was
7.77 in the frequentist approach with a 95% CI of (6.93, 8.61)
and 7.42 in the Bayesian approach with a 95% credible interval
of (5.46, 9.38). See the abstract titled “Cost-Beneﬁcial Accept-
ability Curves: Calculation and Comparison between Frequen-
tist and Bayesian Statistical Approaches in Cost-Beneﬁt
Analysis” for the detailed CBA data and description. CON-
CLUSIONS: The PPC is cost-beneﬁcial over a reasonable range
of cost and beneﬁt values. Results are similar between the fre-
quentist and Bayesian approaches, although interpretation of the
two approaches differs signiﬁcantly.
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OBJECTIVES: To evaluate the inﬂuence of an evidence based
guideline for clinical nutrition on direct cost for enteral and par-
enteral nutrition. METHODS: Annual cost for enteral and par-
enteral nutrition has been analysed. An evidence based guideline
for clinical nutrition was developed in the hospital by a multi-
disciplinary team consisting of medical doctors, nurses, dieticians
and pharmacists. In general a guideline is a comprehensive
approach to the best available evidence for clinical nutrition
(enteral nutrition should be used when ever possible). The guide-
line was then implemented in the hospital by teaching nurses and
doctors. One year after introduction of the guideline the annual
cost were analysed. RESULTS: In 2003 the cost for parenteral
nutrition were €86.908, and for enteral nutrition €16.273. After
establishing the guideline the cost were reduced especially for
parenteral nutrition (parenteral nutrition €52.245, enteral nutri-
tion €16.092). The savings in 2004 were €34.844, (number of
cases and severity of illness detected by disease staging TM
(medstat group) did not change) CONCLUSIONS: The cost
reduction for clinical nutrition could be inﬂuenced by several
factors: 1) It is possible that the regained awareness of costs have
inﬂuenced the behaviour of the clinicians independent of the
guideline, and 2) The implementation of the guideline lead to an
improved knowledge of the clinicians in clinical nutrition and
reduced variance in individual decision making. Thus nutritional
status improved whereas costs were lowered. Further studies are
needed to detect changes in nutritional status of patients 
after having established a guideline. A study has been initiated
(Nutricor).
